Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor [ID6434]

Draft guidance

Draft guidance (downloadable version) (PDF 273 KB)

Committee papers (PDF 7.02 MB)

Equality impact assessment (downloadable version) (PDF 102 KB)

Public committee slides (PDF 758 KB)

Final scope (PDF 176 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 137 KB)

Equality impact assessment (scoping) (PDF 124 KB)

Review proposal consultation

Review proposal paper (MSWord 40 KB)